Unicycive Therapeutics (Unicycive Therapeutics) Debt-to-EBITDA : -0.01 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Unicycive Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.34 Mil. Unicycive Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.37 Mil. Unicycive Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-82.64 Mil. Unicycive Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Unicycive Therapeutics's Debt-to-EBITDA or its related term are showing as below:

UNCY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.25 Med: -0.04 Max: -0.01
Current: -0.02

During the past 5 years, the highest Debt-to-EBITDA Ratio of Unicycive Therapeutics was -0.01. The lowest was -1.25. And the median was -0.04.

UNCY's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs UNCY: -0.02

Unicycive Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Unicycive Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unicycive Therapeutics Debt-to-EBITDA Chart

Unicycive Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.23

-1.25

-0.04

-0.01

-0.03

Unicycive Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial													-0.02	-0.06	-0.05	-0.03	-0.01

Competitive Comparison of Unicycive Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Unicycive Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unicycive Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's Debt-to-EBITDA falls into.

Unicycive Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Unicycive Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.345	+	0.466)	/	-30.178
	=	-0.03

Unicycive Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.343	+	0.372)	/	-82.636
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Unicycive Therapeutics (NAS:UNCY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Unicycive Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Unicycive Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Unicycive Therapeutics (Unicycive Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022

Website

https://www.unicycive.com

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Executives

Sandeep Laumas	director	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra	director	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal	director	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek	other: EVP of Corporate Strategy	4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller	director	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend	officer: Chief Financial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta	officer: EVP, Pharmaceuticals and BD	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta	director, officer: CEO	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022